Madrigal Pharmaceuticals, Inc. closed fiscal year 2025 with $1.3B in total assets, $656.9M in total liabilities and $602.7M in shareholder equity. Total assets rose 20.9% from the prior fiscal year. The table below carries 11 fiscal years, from 2015 to 2025, and the quarters Madrigal Pharmaceuticals, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
MDGL Balance Sheet by Fiscal Year
Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY22Filing | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY17Filing | FY1610-K | FY1510-K |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.3B+20.9% | $1.0B+62.7% | $640.5M+76.7% | $362.6M+32.6% | $273.3M-4.8% | $287.0M-35.1% | $442.1M-8.9% | $485.4M+152.4% | $192.3M+366.7% | $41.2M+11234.5% | $364K |
| Total Liabilities | $656.9M+128.2% | $287.9M+22.4% | $235.2M+42.4% | $165.2M+113.9% | $77.2M+64.2% | $47.0M+84.5% | $25.5M+201.9% | $8.4M-16.0% | $10.1M+109.5% | $4.8M-90.3% | $49.3M |
| Total Equity | $602.7M-20.1% | $754.4M+86.1% | $405.3M+105.3% | $197.4M+0.7% | $196.1M-18.3% | $240.0M-42.4% | $416.6M-12.7% | $477.0M+161.7% | $182.3M+400.6% | $36.4Mn/m | -$48.9M |
MDGL Balance Sheet by Quarter
Figures are in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'24Filing | Q2'24Filing | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.4B+5.3% | $1.2B+22.6% | $1.2B+23.1% | $1.3B+20.9% | $1.4B+26.9% | $1.0B-7.7% | $996.6M-7.9% | $1.0B+62.7% | $1.1B+351.0% | $1.1B+263.6% | $1.1B+225.5% | $640.5M+76.7% |
| Total Liabilities | $807.4M+9.6% | $720.9M+125.7% | $683.9M+139.1% | $656.9M+128.2% | $736.7M+148.8% | $319.4M+31.6% | $286.0M+23.5% | $287.9M+22.4% | $296.1M+37.3% | $242.7M+22.0% | $231.5M+27.0% | $235.2M+42.4% |
| Total Equity | $626.9M+0.2% | $523.7M-24.7% | $543.5M-23.5% | $602.7M-20.1% | $625.7M-19.5% | $696.0M-18.8% | $710.6M-16.5% | $754.4M+86.1% | $777.2M+3393.0% | $857.1M+728.1% | $850.8M+466.7% | $405.3M+105.3% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Madrigal Pharmaceuticals, Inc. financials
Frequently Asked Questions
Madrigal Pharmaceuticals, Inc. closed fiscal year 2025 with $1.3B in total assets, $656.9M in total liabilities and $602.7M in shareholder equity.
Madrigal Pharmaceuticals, Inc. (MDGL) total assets rose by 20.9% year over year, from $1.0B to $1.3B in fiscal year 2025.
Across the 11 fiscal years this page covers, Madrigal Pharmaceuticals, Inc. (MDGL) total assets went from $364K in fiscal year 2015 to $1.3B in fiscal year 2025.
Madrigal Pharmaceuticals, Inc. (MDGL) reported $1.4B in total assets in Q3 2026. This represents an increase of 5.3% from the same quarter a year earlier.
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Madrigal Pharmaceuticals, Inc. (MDGL) reported on that line in every period on record.